Aaron Kantoff

Aaron Kantoff was the founder of Rayzebio, Inc., founded in 2020, serving as Director from 2020 to 2024.
Mr. Kantoff is the founder of Petrichor Scion Therapeutics Management LLC, founded in 2022, serving as General Partner since 2022.
Current jobs include Executive Director-Business Development at Braeburn Pharmaceuticals SPRL; Director at Marengo Therapeutics, Inc.; Director at Silagene, Inc.; Director at Ceptur Therapeutics, Inc.; Director at Tourmaline Sub, Inc. since 2022; and Independent Director at Avalo Therapeutics, Inc. since 2024.
Former jobs include Director at Syntimmune, Inc. from 2014 to 2018; Director at Cure Forward Corp.; Director at Corvidia Therapeutics, Inc. from 2016 to 2019; Director at Marengo Therapeutics, Inc.; Director at Limelight Bio, Inc.; Director at Akero Therapeutics, Inc. from 2018 to 2019; Independent Director at Centessa Pharmaceuticals Plc from 2021 to 2022; Independent Director at Tourmaline Bio, Inc. from 2023 to 2025; Analyst at Rothschild & Co. US, Inc. in 2009; Vice President at Apple Tree Venture Management LLC from 2013 to 2019; and Venture Partner at Medicxi Ventures (Jersey) Ltd. from 2020 to 2021.
Education includes undergraduate studies at The Leonard N Stern School of Business.